NeuroNOS Announces Groundbreaking Research Publication by its CSO Demonstrating Mechanism of Action in Alzheimer’s Disease and Reinforcing Platform’s Strength Across Neurological Disorders

Company Overview - NeuroNOS is a biopharmaceutical company focused on developing treatments for complex neurological disorders, including Autism Spectrum Disorder, brain cancers, and Alzheimer's disease [1][9] - The company is a subsidiary of Beyond Air (NASDAQ: XAIR) and has established a drug development platform aimed at addressing critical gaps in treatment options for neurological conditions [1][10] Recent Research and Developments - NeuroNOS announced the publication of breakthrough research by its Chief Scientific Officer, Prof. Haitham Amal, in the journal Translational Psychiatry, which presents evidence of a novel mechanism in the early stages of Alzheimer's disease [1][3] - The research identifies significant disruptions in nitric oxide (NO)-related pathways and suggests that targeted inhibition of NO production may serve as a promising therapeutic strategy for early-stage Alzheimer's disease [3][4] Market Opportunity - The global brain therapeutics market is substantial and growing, driven by an aging population and increasing prevalence of neurological disorders, with significant unmet medical needs [7] - NeuroNOS's innovative approach positions the company to capitalize on this expanding market by addressing critical treatment gaps for complex brain diseases [7] Strategic Collaborations and Intellectual Property - NeuroNOS has filed five patent families to protect its novel approach and is collaborating with leading international partners for the production of active pharmaceutical ingredients and advanced formulations [4][5] - The company's scientific team includes experts from top hospitals and institutions, including the Hebrew University of Jerusalem, which plays a central role in its research and development efforts [6][10] Clinical Development Plans - NeuroNOS is preparing for clinical trials, with plans to initiate first-in-human trials for autism in the United States in 2026 [4][8] - The company has previously achieved preclinical breakthroughs in autism and glioblastoma models, reinforcing the versatility of its nitric oxide modulation platform [8]